A Urokinase Receptor-Bim Signaling Axis Emerges During EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma

EGFR is the most common genetically altered oncogene in glioblastoma (GBM), but small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to yield durable clinical benefit. Here we show that in two novel model systems of acquired resistance to EGFR TKIs, elevated expression of urokinase plas...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Res
Asıl Yazarlar: Wykosky, Jill, Hu, Jingjing, Gomez, German G., Taylor, Tiffany, Villa, Genaro R., Pizzo, Donald, VandenBerg, Scott R., Thorne, Amy Haseley, Chen, Clark C., Mischel, Paul S., Gonias, Steven. L., Cavenee, Webster K., Furnari, Frank B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297573/
https://ncbi.nlm.nih.gov/pubmed/25432173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2004
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller